4-Chlorobenzoyl berbamine induces apoptosis and G2/M cell cycle arrest through the PI3K/Akt and NF-κB signal pathway in lymphoma cells

Oncology Reports

Volumn 23, Issue 3, 2010, Pages 709-716

  Du, Hua Ping ^a,b,c   Shen, Jia Kun ^a,c   Yang, Min ^a,c   Wang, Yun Gui ^a,c   Yuan, Xiang Gui ^a,c   Ma, Qiu Ling ^a,c   Jin, Jie ^a,c  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c Key of Laboratory Hematopoietic Malignancies   (China)

Author keywords

Apoptosis; Berbamine derivant; Cell cycle; Lymphoma; Nuclear factor B; Phosphatidylinositol 3 kinase Akt

Indexed keywords

4 CHLOROBENZOYL BERBAMINE; BERBAMINE; CYCLIN A; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL GROWTH; CELL PROLIFERATION; DRUG EFFECT; DRUG MECHANISM; LEUKEMIA CELL LINE; LYMPHOMA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAJI CELL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZYLISOQUINOLINES; CELL DIVISION; CELL LINE, TUMOR; CYCLIN B1; G2 PHASE; HUMANS; LYMPHOMA; NF-KAPPA B; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 77349098744     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000688     Document Type: Article

References (33)

1. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H and Bouabdallah R: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346: 235-242, 2002.
2. Vinjamaram S, Czuczman MS and Hernandez-Ilizaliturri FJ: The use of galiximab in non-hodgkin lymphoma. Clin Lymphoma Myeloma 8: 277-282, 2008.
3. O'Connor OA and Czuczman MS: Novel approaches for the treatment of NHL: proteasome inhibition and immune modulation. Leuk Lymphoma 49 (Suppl 1): 59-66, 2008.
4. Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C and Berthou C: Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 350: 1287-1295, 2004.
5. Polgar D, Leisser C, Maier S, Strasser S, Ruger B and Dettke M: Truncated ALK derived from chromosomal translocation t(2;5)(p23;q35) binds to the SH3 domain of p85-PI3K. Mutat Res 570: 9-15, 2005.
6. Querfeld C, Rizvi MA, Kuzel TM, Guitart J, Rademaker A and Sabharwal SS: The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J Invest Dermatol 126: 1641-1647, 2006.
7. Mohammad R, Abubakr Y, Dan M, Aboukameel A, Chow C and Mohamed A: Bcl-2 antisense oligonucleotides are effective against systemic but not central nervous system disease in severe combined immunodeficient mice bearing human t(14;18) follicular lymphoma. Clin Cancer Res 8: 1277-1283, 2002.
8. Heckman CA, Mehew JW and Boxer LM: NF-kappaB activates Bcl-2 expression in t(14;18) lymphoma cells. Oncogene 21: 3898-3908, 2002.
9. Ren Y, Lu L, Guo TB, Qiu J, Yang Y, Liu A and Zhang JZ: Novel immunomodulatory properties of berbamine through selective down-regulation of STAT4 and action of IFN-gamma in experimental autoimmune encephalomyelitis. J Immunol 181: 1491-1498, 2008.
10. Kupeli E, Kosar M, Yesilada E, Husnu K and Baser C: A comparative study on the anti-inflammatory, antinociceptive and antipyretic effects of isoquinoline alkaloids from the roots of Turkish Berberis species. Life Sci 72: 645-657, 2002.
11. Zhao XY, He ZW, Wu D and Xu RZ: Berbamine selectively induces apoptosis of human acute promyelocytic leukemia cells via survivin-mediated pathway. Chin Med J (Engl) 120: 802-806, 2007.
12. Han YQ, Yuan JY, Shi YJ, Zhu Y and Wu SL: Reversal effect of berbamine on multidrug resistance of K562/A02 cells and its mechanism. Zhongguo Shi Yan Xue Ye Xue Za Zhi 11: 604-608, 2003.
13. Li BY, Fu B, Zhao YL and Li WH: Effects of berbamine on intracellular calcium concentration in cultured HeLa cells. Zhongguo Yao Li Xue Bao 20: 1011-1014, 1999.
14. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
15. Galea CA, Wang Y, Sivakolundu SG and Kriwacki RW: Regulation of cell division by intrinsically unstructured proteins: intrinsic flexibility, modularity, and signaling conduits. Biochemistry 47: 7598-7609, 2008.
16. Geng L, Zhang X, Zheng S and Legerski RJ: Artemis links ATM to G2/M checkpoint recovery via regulation of Cdk1-cyclin B. Mol Cell Biol 27: 2625-2635, 2007.
17. Hamacher R, Schmid RM, Saur D and Schneider G: Apoptotic pathways in pancreatic ductal adenocarcinoma. Mol Cancer 7: 64, 2008.
18. Petros AM, Olejniczak ET and Fesik SW: Structural biology of the Bcl-2 family of proteins. Biochim Biophys Acta 1644: 83-94, 2004.
19. Woodgett JR: Recent advances in the protein kinase B signaling pathway. Curr Opin Cell Biol 17: 150-157, 2005.
20. Garcia MG, Alaniz LD, Cordo Russo RI, Alvarez E and Hajos SE: PI3K/Akt inhibition modulates multidrug resistance and activates NF-kappaB in murine lymphoma cell lines. Leuk Res 33: 288-296, 2008.
21. Uddin S, Hussain AR, Siraj AK, Manogaran PS, Al-Jomah NA and Moorji A: Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 108: 4178-1486, 2006.
22. Borlado LR, Redondo C, Alvarez B, Jimenez C, Criado LM, and Flores J: Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo. FASEB J 14: 895-903, 2000.
23. Rudelius M, Pittaluga S, Nishizuka S, Pham TH, Fend F and Jaffe ES: Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 108: 1668-1676, 2006.
24. Lawlor MA and Alessi DR: PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci 114: 2903-2910, 2001.
25. Lee S, Choi EJ, Jin C and Kim DH: Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol 97: 26-34, 2005.
26. Steelman LS, Abrams SL, Whelan J, Bertrand FE, Ludwig DE and Basecke J: Contributions of the Raf/MEK/ERK, PI3K/ PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 22: 686-707, 2008.
27. Mackenzie GG, Queisser N, Wolfson ML, Fraga CG, Adamo AM and Oteiza PI: Curcumin induces cell-arrest and apoptosis in association with the inhibition of constitutively active NF-kappaB and STAT3 pathways in Hodgkin's lymphoma cells. Int J Cancer 123: 56-65, 2008.
28. Ohsugi T and Koito A: Current topics in prevention of human T-cell leukemia virus type I infection: NF-kappa B inhibitors and APOBEC3. Int Rev Immunol 27: 225-253, 2008.
29. Hagenbeek TJ and Spits H: T-cell lymphomas in T-cell-specific Pten-deficient mice originate in the thymus. Leukemia 22: 608-619, 2008.
30. Herranz M, Urioste M, Santos J, Martinez-Delgado JB, Rivas C, Benitez J and Fernandez-Piqueras J: Allelic losses and genetic instabilities of PTEN and p73 in non-Hodgkin lymphomas. Leukemia 14: 1325-1327, 2000.
31. Fridberg M, Servin A, Anagnostaki L, Linderoth J, Berglund M and Soderberg O: Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: higher expression of ZAP70 and PKC-beta II in the nongerminal center group and poor survival in patients deficient in nuclear PTEN. Leuk Lymphoma 48: 2221-2232, 2007.
32. Zhou M, Gu L, Findley HW, Jiang R and Woods WG: PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. Cancer Res 63: 6357-6362, 2003.
33. Dal Col J, Zancai P, Terrin L, Guidoboni M, Ponzoni M and Pavan A: Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. Blood 111: 5142-5151, 2008.